CLOs on the Move

La Jolla Bioengineering Institute

www.ljbi.org

 
La Jolla Bioengineering Institute is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 50K-100K
  • Annual Revenue: $1-10 Million
  • www.ljbi.org
  • 3535 General Atomics Ct Ste 210
    San Diego, CA USA 92121
  • Phone: 858.456.7500

Executives

Name Title Contact Details

Similar Companies

VLST

VLST is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celldex

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body`s immune response. Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company`s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in immuno-oncology.

Medical Tactile

Medical Tactile is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BNBI

Managed by Battelle National Biodefense Institute (BNBI) as a Federally Funded Research and Development Center (FFRDC), National Biodefense Analysis and Countermeasures Center is the first laboratory built for DHS – a national resource to understand th...

Batu Biologics

Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer:” the tumor blood vessels. Batu’s flagship therapeutic, ValloVax™, is an angiogenesis targeting cancer vaccine in the late stages of preclinical development. Batu Biologics plans to file an Investigational New Drug (IND) application for ValloVax in Q1 of 2015, seeking clinical approval to treat patients with lung cancer.